Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Mylan NV    MYL   NL0011031208

MYLAN NV (MYL)
My previous session
Most popular
  Report  
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
01/14/2019 01/15/2019 01/16/2019 01/17/2019 01/18/2019 Date
29.51(c) 29.35(c) 29.26(c) 29.55(c) 29.59(c) Last
2 644 088 3 621 932 3 088 244 4 706 829 3 848 249 Volume
-0.14% -0.54% -0.31% +0.99% +0.14% Change
More quotes
Financials (USD)
Sales 2018 11 477 M
EBIT 2018 3 384 M
Net income 2018 441 M
Debt 2018 12 356 M
Yield 2018 -
Sales 2019 11 925 M
EBIT 2019 3 631 M
Net income 2019 1 109 M
Debt 2019 10 719 M
Yield 2019 -
P/E ratio 2018 14,19
P/E ratio 2019 11,42
EV / Sales2018 2,41x
EV / Sales2019 2,18x
Capitalization 15 258 M
More Financials
Company
Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic, brand name and over-the-counter (OTC) products in a range of dosage forms and therapeutic categories. It operates through three segments on a geographic basis, North... 
Sector
Pharmaceuticals
Calendar
02/27Earnings Release
More about the company
Surperformance© ratings of Mylan NV
Trading Rating : Investor Rating :
More Ratings
Latest news on MYLAN NV
01/16NOVARTIS : Sandoz Launches EpiPen Generic -- Update
DJ
01/16NOVARTIS : Sandoz Launches EpiPen Generic
DJ
01/15European nations weigh impact of Brexit on drug supplies
RE
2018MYLAN : to Present at the 37th Annual J.P. Morgan Healthcare Conference
PR
2018MYLAN : Launch of Generic Lialda® Delayed-Release Tablets Expands Mylan's Gastro..
PR
2018MYLAN : Adds First Generic for Canasa® Rectal Suppository to Growing Gastroenter..
PR
2018MYLAN : Sanofi's Formulation Patents on Multibillion-Dollar Lantus® are Invalida..
PR
2018FDA Issues Warning Letter to Zhejiang Huahai in Valsartan Recall
DJ
2018MYLAN : Expands its Voluntary Nationwide Recall of Valsartan Tablets, USP, Amlod..
PR
2018MYLAN : Expands Gastroenterology Portfolio with Launch of Generic for Prevacid® ..
PR
More news
Analyst Recommendations on MYLAN NV
More recommendations
Sector news : Pharmaceuticals - NEC
01/18ELI LILLY AND : Lilly Reports Favorable Cyramza Results in Phase 3 Liver Cancer ..
DJ
01/18ABBVIE : Says Imbruvica Didn't Meet Endpoints in Pancreatic Cancer Study
DJ
01/18Samsung Bioepis biosimilar to Roche's Herceptin wins FDA nod
RE
01/18FDA Approves Herceptin Biosimilar Ontruzant Breast Cancer Drug
DJ
01/18ELI LILLY AND : Sarcoma Drug Combo Proves Ineffective in Trials--Update
DJ
More sector news : Pharmaceuticals - NEC
Chart MYLAN NV
Duration : Period :
Mylan NV Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MYLAN NV
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 17
Average target price 42,3 $
Spread / Average Target 43%
EPS Revisions
Managers
NameTitle
Heather M. Bresch Chief Executive Officer & Executive Director
Rajiv Malik President & Executive Director
Robert J. Coury Executive Chairman
Haribabu Bodepudi Chief Operating Officer
Kenneth Scott Parks Chief Financial Officer
Sector and Competitors
1st jan.Capitalization (M$)
MYLAN NV7.99%15 258
JOHNSON & JOHNSON0.03%350 508
PFIZER-2.70%246 674
NOVARTIS5.66%227 840
ROCHE HOLDING LTD.6.16%223 498
MERCK AND COMPANY-0.71%197 291